A Randomized, Observer-Blinded, Dose-Escalation Phase 1 Study to Assess the Safety and Immunogenicity of Three Different Dose Levels of a Live-Attenuated Chikungunya Virus Vaccine Candidate (VLA1553) in Healthy Volunteers Aged 18 To 45 Years
Phase of Trial: Phase I
Latest Information Update: 19 Mar 2018
At a glance
- Drugs VLA 1553 (Primary)
- Indications Chikungunya virus infections
- Focus Adverse reactions
- Sponsors Valneva
- 13 Mar 2018 According to a Valneva media release, first data are expected to be available early 2019.
- 13 Mar 2018 Status changed from not yet recruiting to recruiting, according to a Valneva media release.
- 18 Dec 2017 Status changed from planning to not yet recruiting.